Compass Therapeutics, Inc. (CMPX) Cash Flow Statement
Compass Therapeutics, Inc. (CMPX) generated -$56.1M of operating cash flow over the twelve months to 2026-06-30, spent $265000 on capital expenditure and had free cash flow of -$56.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CMPXCompass Therapeutics, Inc.Follow CMPX — free
—
Price chart with a free account
- Market cap
- 137.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -44.9 | -49.1 | -56.1 | |
| Capital expenditure | 0.0 | 0.0 | -0.3 | |
| Free cash flow | -44.9 | -49.2 | -56.4 | |
| Stock-based compensation | 8.6 | 8.4 | — |
USD millions · SEC XBRL
Compass Therapeutics, Inc. — questions
- What is Compass Therapeutics, Inc.'s operating cash flow?
- -$56.1M over the twelve months to 2026-06-30.
- How much does Compass Therapeutics, Inc. spend on capital expenditure?
- $265000 over the twelve months to 2026-06-30.
- What is Compass Therapeutics, Inc.'s free cash flow?
- -$56.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Compass Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.